We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Biocept Inc | NASDAQ:BIOC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.4349 | 0.37 | 0.3799 | 0 | 01:00:00 |
From May 2019 to May 2024
SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the management of cancer patients, announces that President and CEO Michael W. Nall will present a corporate overview at the 19th Annual BIO CEO and Investor Conference on Monday, February 13, 2017, at 2:00 p.m. Eastern time (11:00 a.m. Pacific time). The conference is being held at the Waldorf Astoria New York hotel in New York City.
A live webcast of the corporate presentation at the BIO CEO and Investor Conference will be available on the Company's website at ir.biocept.com. A replay of the webcast will be available for 90 days.
About BIO CEO and Investor Conference
The BIO CEO and Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. The event features plenary sessions, fireside chats, business roundtables, therapeutic workshops, company presentations and One-on-One PartneringTM meetings.
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-19th-annual-bio-ceo-and-investor-conference-300402176.html
SOURCE Biocept, Inc.
Copyright 2017 PR Newswire
1 Year Biocept Chart |
1 Month Biocept Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
